Mammary Cell News Volume 10.02 | Jan 18 2018

TOP STORY

New Way to Target the Growth of Breast Cancer Cells

Researchers have found a new way of halting the growth of breast cancer cells. They hope that their discoveries can be further developed into a new way of treating breast cancer, and possibly other types of cancer. [Press release from the Karolinska Institutet discussing online prepublication in Nature Communications] Press Release | Full Article

(Ranked by impact factor of the journal)

HIF Signaling in Osteoblast-Lineage Cells Promotes Systemic Breast Cancer Growth and Metastasis in Mice

Investigators found that activation of hypoxia-inducible factor (HIF) signaling in osteoprogenitor cells increases blood levels of the chemokine C-X-C motif ligand 12, which leads to a systemic increase of breast cancer cell proliferation and dissemination through direct activation of the CXCR4 receptor. [Proc Natl Acad Sci USA] Abstract

Kindlin-1 Promotes Pulmonary Breast Cancer Metastasis

Researchers showed that in a mouse model of polyomavirus middle T antigen-induced mammary tumorigenesis, loss of Kindlin-1 reduced early pulmonary arrest and later development of lung metastasis. [Cancer Res] Abstract

AMPK-AKT Double Negative Feedback Loop in Breast Cancer Cells Regulates Their Adaptation to Matrix Deprivation

Scientists illuminated mechanisms that enable reversible matrix attachment by breast cancer cells. Matrix deprival triggered AMPK activity and concomitantly inhibited AKT activity by upregulating the AKT phosphatase PHLPP2. [Cancer Res] Abstract | Full Article

Conditional Knockout of N-Myc and STAT Interactor Disrupts Normal Mammary Development and Enhances Metastatic Ability of Mammary Tumors

Investigators demonstrated that N-Myc and STAT interactor (Nmi: murine) has a distinct role in the differentiation process of mammary luminal epithelial cell compartment and developmental aberrations resulting from Nmi absence contribute to metastasis and demonstrates that aberration in normal developmental program can lead to metastatic disease, highlighting the contribution and importance of luminal progenitor cells in driving metastatic disease. [Oncogene] Full Article

Orai3 Calcium Channel and Resistance to Chemotherapy in Breast Cancer Cells: The P53 Connection

The authors investigated major changes induced by Orai3 overexpression, including downstream signaling mechanisms involved in breast cancer chemotherapy resistance. Resistance was dependent on external calcium presence and thus Orai3 functionality. [Cell Death Differ] Abstract

Epigenetic Silencing of TAP1 in Aldefluor⁺ Breast Cancer Stem Cells Contributes to Their Enhanced Immune Evasion

To investigate the ability of breast cancer stem cells to evade immune detection scientists identified a highly tumorigenic population in a spontaneous murine mammary tumor based on increased aldehyde dehydrogenase activity. [Stem Cells] Abstract

MCL-1 Is a Prognostic Indicator and Drug Target in Breast Cancer

The authors report associations between high MCL-1 and poor prognosis in specific subtypes of breast cancer including triple-negative breast cancer, an aggressive form that lacks targeted treatment options. Deletion of MCL-1 in the mammary epithelium of genetically engineered mice revealed an absolute requirement for MCL-1 in breast tumorigenesis. [Cell Death Dis] Full Article

Human Placental-Derived Adherent Stromal Cells Co-Induced with TNF-α and IFN-γ Inhibit Triple-Negative Breast Cancer in Nude Mouse Xenograft Models

In vitro co-culture studies of induced-adherent stromal cells (ASCs) with MDA-MB-231 human breast carcinoma cells, a model representing triple-negative breast cancer, supports a mechanism involving immunomodulation and angiogenesis inhibition. In vivo studies in nude mice showed that intramuscular administration of induced-ASCs halted MDA-MB-231 cell proliferation, and inhibited tumor progression and vascularization. [Sci Rep] Full Article | Press Release

COX-2 Induces Oncogenic Micro RNA miR655 in Human Breast Cancer

Scientists showed that Cyclooxygenase-2 over-expression induces an oncogenic microRNA, miR655, in human breast cancer cells by activation of EP4. miR655 expression positively correlated with COX-2 in genetically disparate breast cancer cell lines and increased in all cell lines when grown as spheroids, implicating its link with stem-like cells. [Sci Rep] Full Article

The mTOR Inhibitor AZD8055 Overcomes Tamoxifen Resistance in Breast Cancer Cells by Down-Regulating HSPB8

Researchers report that small heat protein beta-8 (HSPB8) may serve as an important molecule in tamoxifen resistance. HSPB8 expression was enhanced in MCF-7 cells resistant to tamoxifen compared to parent cells. They found that the anti-proliferative activity of AZD8055 was positively correlated with the HSPB8 expression level in ER⁺ breast cancer cells. [Acta Pharmacol Sin] Abstract

Using Gene Expression Data to Direct Breast Cancer Therapy: Evidence from a Preclinical Trial

The authors review the classification of breast cancers and discuss therapy of hormone positive, HER2 positive, and triple negative breast cancers. Model systems for breast cancer are examined allowing for a preclinical trial using a personalized medicine approach to be tested. [J Mol Med (Berl)] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with Anti-PD-L1 Cancer Immunotherapy in Breast Cancer

Syndax Pharmaceuticals, Inc. announced a new clinical collaboration with Genentech, a member of the Roche Group. As part of the collaboration, the two companies will evaluate the combination of Syndax’s entinostat, an oral, small molecule, class I HDAC inhibitor, and Genentech’s programmed cell death ligand 1 blocking antibody, atezolizumab (TECENTRIQ^®), in patients with second-line hormone receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer. [Syndax Pharmaceuticals] Press Release

Context Therapeutics Announces the Acquisition of Apristor^™ (Onapristone XR), an Investigational Phase II Drug for Metastatic Breast Cancer

Context Therapeutics announced that it has acquired worldwide rights to Apristor. Onapristone has been extensively studied and has established efficacy in two Phase II metastatic breast cancer clinical trials. [Context Therapeutics (Business Wire, Inc.)] Press Release

OncoSec Provides Encouraging Clinical Observations Related to Triple Negative Breast Cancer Study

OncoSec Medical Incorporated announced preliminary clinical observations related to its pilot biomarker OMS-I140 clinical trial of ImmunoPulse^® IL-12 in patients with metastatic triple negative breast cancer. [OncoSec Medical Incorporated (PR Newswire Association LLC.)] Press Release

LYNPARZA^® (Olaparib) Approved by US FDA in Germline BRCA-Mutated Metastatic Breast Cancer

AstraZeneca and Merck & Co., Inc. announced that the FDA has approved Lynparza, for use in patients with deleterious or suspected deleterious germline BRCA-mutated, human epidermal growth factor receptor 2-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. [AstraZeneca] Press Release

In Trump’s First Year, Science Advice Sees a Marked Decline

Since U.S. President Donald Trump took office, expert panels that provide key federal agencies with science advice have had fewer members and met less often than at any time since 1997, when the government started tracking such numbers, a new analysis concludes. [ScienceInsider] Editorial

What a US Government Shutdown Would Mean for Science

The clock is ticking for US lawmakers, who have fewer than two days to pass a new budget or face a government shutdown. Nature explains why politicians are struggling to reach a deal, what is at stake for science and whether a crisis can be avoided. [Nature News] Editorial

NEW The Stem Cell Niche Conference 2018
May 27-31, 2018
Copenhagen, Denmark

Visit our events page to see a complete list of events in the community.

NEW Cancer Bioinformatician – Breast Cancer Research (The Institute of Cancer Research)

Postdoctoral Training Fellow – Molecular Engineering (The Institute of Cancer Research)

Scientific Officer – Breast Cancer Research (The Institute of Cancer Research)

Higher Scientific Officer – Breast Cancer Research (The Institute of Cancer Research)

Postdoctoral Associate – Breast Cancer Research (University of Miami)

PhD Program – Breast Cancer (Institut Curie)

Professor – Tenure System – Cancer Biology (Michigan State University)

Postdoctoral Associate – Melanoma and Breast Cancer Research (University of Miami)

Postdoctoral Fellowship – Breast Cancer Research (Geisel School of Medicine at Dartmouth)

Postdoctoral Position – Transcriptomics and Cancer Epigenetics (Universität Basel)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.